^
Association details:
Biomarker:FBXW7 mutation
Cancer:T Acute Lymphoblastic Leukemia
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia

Excerpt:
We then investigated the relevance of NOTCH1 and/or FBXW7 mutations in relation to treatment outcome. For the DCOG cohort, mutations in NOTCH1 and/or FBXW7 tended toward poor treatment outcome. The 5-year EFS rates for patients with NOTCH1 mutations only compared with wild-type patients were 57±8% versus 76±8% (P=0.08) for the DCOG cohort but 63±8 versus 64±10% for the COALL cohort (P=0.99, Figures 3a and b). Inclusion of FBXW7 mutations resulted in 5-year EFS rates of 58±7 versus 74±9% (P=0.16) for the DCOG cohort and 63±8 versus 68±10% for the COALL cohort (P=0.90)...
DOI:
10.1182/blood-2005-12-4956